Måske vi skulle forsøge at samle lidt viden om Humax-TF ADC´s chancer i cervical cancer - vi kender ikke meget til data endnu, men når man lige ser hvad jeg hurtigt kunne støve op en sen nattetime, så ligger tisotumab vedotin nogenlunde på niveau med andre behandlinger på respons.
Her er først lige hvad der er godkendt til behandlingen i dag:
https://www.cancer.gov/about-cancer/treatment/drugs/cervical
Nu har jeg hurtigt kigget igennem nogle få abstracts der blev præsenteret indenfor cervical cancer på ASCO 2017 - her er lige et par enkelte uddrag af antistoffer, da det vel er det vi kan sammenligne med i første omgang:
Pembrolizumab for previously treated advanced cervical squamous cell cancer: Preliminary results from the phase 2 KEYNOTE-158 study:Results: Among the first 47 patients with advanced cervical cancer who enrolled, ORR was 17% (95% CI, 8%-31%), with 3 confirmed and 5 unconfirmed responses. 41 (87%) patients had PD-L1-positive tumors, and ORR was independent of PD-L1 status. Among the 15 patients who had ≥27 weeks of follow-up, ORR was 27% (95% CI 8%-55%), with 3 confirmed responses and 1 unconfirmed response. Safety and updated efficacy data for 83 patients with ≥27 weeks of follow-up will be available for presentation.
http://abstracts.asco.org/199/AbstView_199_194350.html
An open-label, multicohort, phase I/II study of nivolumab in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in recurrent or metastatic (R/M) cervical, vaginal, and vulvar cancers: Results: Of 24 treated patients (pts), 19 had cervical and 5 had vaginal or vulvar cancer; median age was 51 y. At a median follow-up of 31 wks (range: 6-38), ORR was 20.8% (Table), and disease control rate (ORR + SD) was 70.8%. All responses were in pts with cervical cancer (ORR, 26.3%) and were observed regardless of PD-L1 or HPV status or number of prior R/M therapies. Median PFS was 5.5 mo (95% CI: 3.5, NR); median OS was NR
http://abstracts.asco.org/199/AbstView_199_184153.html
Her også lige godkendelsen af bevazizumab (Avastin):
http://www.ucirvinehealth.org/news/2014/08/cervical-cancer-therapy-approved
Det var blot en start - kom gerne med det i finder !
Mvh
Sukkeralf
Her er først lige hvad der er godkendt til behandlingen i dag:
https://www.cancer.gov/about-cancer/treatment/drugs/cervical
Nu har jeg hurtigt kigget igennem nogle få abstracts der blev præsenteret indenfor cervical cancer på ASCO 2017 - her er lige et par enkelte uddrag af antistoffer, da det vel er det vi kan sammenligne med i første omgang:
Pembrolizumab for previously treated advanced cervical squamous cell cancer: Preliminary results from the phase 2 KEYNOTE-158 study:Results: Among the first 47 patients with advanced cervical cancer who enrolled, ORR was 17% (95% CI, 8%-31%), with 3 confirmed and 5 unconfirmed responses. 41 (87%) patients had PD-L1-positive tumors, and ORR was independent of PD-L1 status. Among the 15 patients who had ≥27 weeks of follow-up, ORR was 27% (95% CI 8%-55%), with 3 confirmed responses and 1 unconfirmed response. Safety and updated efficacy data for 83 patients with ≥27 weeks of follow-up will be available for presentation.
http://abstracts.asco.org/199/AbstView_199_194350.html
An open-label, multicohort, phase I/II study of nivolumab in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in recurrent or metastatic (R/M) cervical, vaginal, and vulvar cancers: Results: Of 24 treated patients (pts), 19 had cervical and 5 had vaginal or vulvar cancer; median age was 51 y. At a median follow-up of 31 wks (range: 6-38), ORR was 20.8% (Table), and disease control rate (ORR + SD) was 70.8%. All responses were in pts with cervical cancer (ORR, 26.3%) and were observed regardless of PD-L1 or HPV status or number of prior R/M therapies. Median PFS was 5.5 mo (95% CI: 3.5, NR); median OS was NR
http://abstracts.asco.org/199/AbstView_199_184153.html
Her også lige godkendelsen af bevazizumab (Avastin):
http://www.ucirvinehealth.org/news/2014/08/cervical-cancer-therapy-approved
Det var blot en start - kom gerne med det i finder !
Mvh
Sukkeralf
Lidt monoterapidata for bevacizumab på side 13..
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4037327/#!po=41.6667
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4037327/#!po=41.6667
19/6 2017 13:04 Kænned 0
75647 Hej Sukkeralf
Super god ide med oversigten her. Lige et temmelig banalt spørgsmål dog. Er en responsrate på 17% godt? For en uindviet som jeg lyder det som et enormt lavt tal. Er det normalt at det ikke er højere?
Super god ide med oversigten her. Lige et temmelig banalt spørgsmål dog. Er en responsrate på 17% godt? For en uindviet som jeg lyder det som et enormt lavt tal. Er det normalt at det ikke er højere?
Responsraterne kommer meget an på sygdommen, hvor syge patienterne er og om det er monoterapi eller kombinationsbehandling.
Hvad der forventes i livmoderhalskræft ved jeg ikke eksakt, men eksempelvis nævnte Jan på et tidspunkt at daratumumab som minimum helst skulle opnå 20% som monoterapi i "4 linie" MM.
Så 17% er formentlig i underkanten, mens tisotumabs responsrate på lige over 30% godt kunne være nok - men responsraten er jo kun en lille del af billedet, så også derfor det pt er svært at vurdere om der er en fremtid for tisotumab.
Jeg synes det er fair at det umiddelbart ikke giver den vilde kursreaktion indtil vi får mere viden.
Mvh
Sukkeralf
Hvad der forventes i livmoderhalskræft ved jeg ikke eksakt, men eksempelvis nævnte Jan på et tidspunkt at daratumumab som minimum helst skulle opnå 20% som monoterapi i "4 linie" MM.
Så 17% er formentlig i underkanten, mens tisotumabs responsrate på lige over 30% godt kunne være nok - men responsraten er jo kun en lille del af billedet, så også derfor det pt er svært at vurdere om der er en fremtid for tisotumab.
Jeg synes det er fair at det umiddelbart ikke giver den vilde kursreaktion indtil vi får mere viden.
Mvh
Sukkeralf
